Expanded Access to Tipifarnib

NCT04809233CI-TRIAL-00116121KuraoncologyavailableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	CURATED_BROADER	0.80

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Tipifarnib	Drug	Tipifarnib	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion/Exclusion Criteria:

Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).

Adult, ages 18+.

Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.

Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.

Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology

References

Publications (0)

Data not yet available

No reference posted for this study.